Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alteplase in Chinese Acute Ischemic Stroke (3-4.5h)
NCT02930837Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alteplase in ischemic stroke, sponsored by Boehringer Ingelheim. Primary endpoints: Percentage of Patients With Modified Rankin Scale (mRS 0-1) (Favourable Outcome) at 90 days and Percentage of Patients With Symptomatic Intracranial Haemorrhage at 90 days. Started Nov 2016; status: completed.
02
Drugs
alteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02930837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930837.